

FOREWORD	1
CHAPTER ONE: OPHTHALMIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM031C):	2
INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY.....	2
SCOPE OF REPORT.....	3
INTENDED AUDIENCE.....	4
INFORMATION SOURCES	5
RELATED BCC REPORTS.....	5
BCC ONLINE SERVICES	6
DISCLAIMER.....	6
SUMMARY.....	6
<i>TABLE 1 GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, THROUGH 2014 (\$ MILLIONS)</i>	7
<i>FIGURE 1 GLOBAL OPHTHALMIC FORECAST BY DISEASE CLASS, 2008-2014 (\$ MILLIONS)</i>	8
OVERVIEW.....	9
HISTORY AND CURRENT STATE OF OPHTHALMOLOGY	
DISEASE.....	9
Established Drug Classes in Ophthalmology.....	10
Emerging Drug Classes.....	10
VEGF-Trap Eye	10
Combination Therapies	11
Competition between VEGF Inhibitors in Wet AMD	11
<i>TABLE 2 NOTABLE EVENTS IN LUCENTIS VERSUS AVASTIN: PREVIOUS AND EXPECTED</i>	12
Expected Outcome of CATT trial: Avastin v. Lucentis.....	12
Genetic Specifications of Ophthalmic Disease	13
<i>TABLE 3 SUMMARY OF KNOWN GENES INFLUENCING DISEASE</i>	14
Summary Pipeline of Drugs in Development.....	14
<i>TABLE 4 RECENTLY APPROVED DRUGS, 2009</i>	15
<i>TABLE 5 SUMMARY PIPELINE FORECAST, 2012-2014</i>	15
INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS.....	15
INDUSTRY STRUCTURE.....	15
Market Concentration and Price Sensitivity.....	16
<i>TABLE 6 COMPANY BY DISEASE CLASS, 2009 REVENUE (\$ MILLIONS)</i>	17
Competitive Factors	17
<i>TABLE 7 LARGE REVENUE, BRANDED DRUG SALES COMING OFF PATENT, 2009</i>	18

CHAPTER TWO: GLOBAL MARKETS FOR ORPHAN DRUGS (PHM038C).....	19
INTRODUCTION	19
STUDY GOAL AND OBJECTIVES	19
REASONS FOR DOING THE STUDY.....	20
INTENDED AUDIENCE.....	20
SCOPE OF REPORT.....	21
INFORMATION SOURCES AND METHODOLOGY	21
AUTHOR’S CREDENTIALS	22
RELATED REPORTS FROM BCC RESEARCH.....	22
SUMMARY.....	23
<i>TABLE 8 GLOBAL ORPHAN DRUGS DEMAND BY VALUE, THROUGH 2014 (\$ MILLIONS).</i>	24
<i>FIGURE 2 GLOBAL ORPHAN DRUGS DEMAND BY VALUE, 2008-2014 (\$ MILLIONS).</i>	25
OVERVIEW.....	25
DEFINITION OF AN ORPHAN DRUG.....	25
HISTORY OF ORPHAN DRUG LEGISLATION	26
First Legislation on Orphan Drugs.....	26
Amendments to the ODA.....	26
Bills Passed in 2002 Increased Funding and Established the Office of Rare Diseases	26
Orphan Drug Legislation — Global Status	26
INCENTIVES FOR ORPHAN DRUG DEVELOPMENT.....	27
THE NEED FOR INCENTIVES	27
<i>TABLE 9 NUMBER OF ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR BY U.S. FDA, 1983-2009</i>	27
APPLICATIONS FOR ORPHAN DRUG DESIGNATIONS HAVE DOUBLED.....	28
PROFITABILITY OF ORPHAN DRUGS.....	28
Market Exclusivity	28
No Regulatory Restrictions on Pricing	29
Off-Label Use.....	29
CHALLENGES FOR EFFECTIVE USE OF THE ODA	30
MARKET EXCLUSIVITY VERSUS PATENT PROTECTION.....	30
MARKET SIZE AND KEY PLAYERS.....	31
<i>TABLE 10 TOP 10 COMPANIES IN THE ORPHAN DRUG MARKET AND THEIR MARKET SHARES (%)</i>	32
THE ORPHAN DRUG ACT — A BONUS FOR BIOTECH	32
BIG PHARMA IS ENTERING THE ORPHAN DRUGS SECTOR AGGRESSIVELY	32
CONCERNS ABOUT THE ORPHAN DRUG ACT.....	33
COST-EFFECTIVENESS.....	34
PRICING OF ORPHAN DRUGS.....	34

<i>TABLE 11 SOME EXAMPLES OF HIGHLY EXPENSIVE ORPHAN DRUGS AND THEIR PRICES</i>	35
High-Priced Orphan Drugs Leading to Price Control	
Measures by Governments	36
<i>TABLE 12 SOME OF THE RECENT CONTROVERSIES RELATED TO ORPHAN DRUGS PRICING</i>	37
ACCESS TO ORPHAN DRUGS AND REIMBURSEMENT —	
CURRENT PRACTICES	38
Orphan Drug Access and Reimbursement Scenario in the	
U.S.	38
Access and Reimbursement Scenario in Europe.....	38
<i>TABLE 13 ORPHAN DRUG ACCESS AND REIMBURSEMENT PRACTICES IN EUROPEAN COUNTRIES</i>	39
<i>TABLE 13 (CONTINUED)</i>	40
<i>TABLE 13 (CONTINUED)</i>	41
Call for Unification of Orphan Drug Access Across Europe	41
INNOVATIVE APPROACHES OF PRICING AND	
REIMBURSEMENT	42
<i>TABLE 14 EMERGING TRENDS IN PRICING AND REIMBURSEMENT OF HIGH-PRICED DRUGS</i>	42
<i>TABLE 14 (CONTINUED)</i>	43
CHAPTER THREE: DRUG-DEVICE COMBINATIONS: THE GLOBAL	
MARKET (PHM045B).....	44
INTRODUCTION	44
STUDY GOALS AND OBJECTIVES	44
REASONS FOR DOING THIS STUDY AND ITS	
IMPORTANCE.....	44
INTENDED AUDIENCE.....	45
SCOPE OF REPORT.....	45
METHODOLOGY AND INFORMATION SOURCES	45
ANALYST CREDENTIALS	46
SUMMARY.....	46
SCOPE OF THE INDUSTRY	46
DRUG-DEVICE COMBINATIONS: THE GLOBAL MARKET	47
TECHNOLOGY AND PATENT ACTIVITY.....	48
THE CENTRAL ROLE OF THE FDA.....	48
<i>TABLE 15 SALES OF DRUG DEVICE COMBINATION PRODUCTS, THROUGH 2014 (\$ BILLIONS)</i>	49
<i>FIGURE 3 SALES OF DRUG DEVICE COMBINATION PRODUCTS, 2008-2014 (\$ BILLIONS)</i>	49
CURRENT STATUS OF THE DRUG DEVICE COMBINATION	
INDUSTRY	50
OVERVIEW	50
ROLE OF THE FDA.....	50

<i>TABLE 16 RECENT EXAMPLES OF FDA APPROVED COMBINATION PRODUCTS.....</i>	<i>51</i>
<i>TABLE 16 (CONTINUED).....</i>	<i>52</i>
OFFICE OF COMBINATION PRODUCTS ORGANIZATIONAL STRUCTURE	52
HIGHLY ADVANCED TECHNOLOGIES ARE A MARKET CORE.....	52
EXAMPLES OF THE MOST PATH-BREAKING PRODUCTS.....	53
FDA CLASSIFICATION SCHEME FOR INDIVIDUAL SEGMENTS	54
<i>TABLE 17 FDA CLASSIFICATION SCHEME FOR COMBINATION PRODUCTS.....</i>	<i>55</i>
THE RELATION BETWEEN NANOTECHNOLOGY AND COMBINATION PRODUCTS.....	55
FDA TRENDS IN REVIEWING COMBINATION PRODUCTS	55
<i>FIGURE 4 COMBINATION PRODUCT APPLICATIONS AT FDA, 2003-2007 (NUMBER OF SUBMISSIONS).....</i>	<i>56</i>
<i>TABLE 18 FDA COMBINATION PRODUCT CATEGORIES, FY 2004.....</i>	<i>57</i>
<i>TABLE 19 FDA COMBINATION PRODUCT CATEGORIES, FY 2005 (NUMBERS AND TYPES OF COMBINATION PRODUCTS)</i>	<i>58</i>
NANOTECH COMBINATION PRODUCTS	59
OVERVIEW	59
NATIONAL NANOTECHNOLOGY INITIATIVE (NNI).....	59
NANOTECH REGULATORY ENVIRONMENT.....	60
Nanotech Regulatory Environment (Continued)	61
COMBINATION NANOTECHNOLOGY PRODUCT RESEARCH.....	62
Nanodiamond Drug Devices for Cancer Treatment.....	63
Nanotechnology-Magnetism Combination in Tiny Implantable Device for Drug Delivery	64
Implants Using Conducting Polymer Nanotubes.....	65
Calcium Phosphate Nanoparticles for Drug Delivery.....	66
Nano-scale Delivery Optimizes Chemotherapy Regimes.....	67
Drug Infused Nanoparticles.....	68
Drug Infused Nanoparticles (Continued).....	69
Encapsulation of Drug Treatments in Nanoparticles	70
Silicon Nanowires for Drug Delivery	70
Minute Antibacterial Particles Destroy Drug-Resistant Germs.....	71
Biodegradable Cationic Core-Shell Nanoparticles for Co-delivery of Drugs and Genes.....	72
Stimuli-Sensitive Core-Shell Nanoparticles for Cancer Therapy.....	72
Polymer-Based Non-Viral Gene Carriers	73

POTENTIAL HEALTH EFFECTS: IMPACT ON NANO INDUSTRY.....	73
Potential Health Effects: ... (Continued).....	74
<i>TABLE 20 REVENUES ATTRIBUTABLE TO NANOTECHNOLOGY- BASED DRUG-DEVICE COMBINATIONS, THROUGH 2014 \$ MILLIONS</i>	75
CHAPTER FOUR: CARDIOVASCULAR THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM024B)	
INTRODUCTION	76
STUDY GOALS AND OBJECTIVES	76
REASONS FOR DOING THE STUDY.....	76
SCOPE OF REPORT.....	77
INTENDED AUDIENCE.....	78
METHODOLOGY AND INFORMATION SOURCES.....	79
RELATED BCC REPORTS.....	79
BCC ONLINE SERVICES	79
DISCLAIMER.....	80
SUMMARY.....	80
<i>TABLE 21 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, THROUGH 2015 (\$ MILLIONS)</i>	80
<i>FIGURE 5 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, 2007-2015 (\$ MILLIONS)</i>	81
OVERVIEW.....	82
CURRENT STATE OF CARDIOVASCULAR DISEASE	82
<i>FIGURE 6 LEADING CAUSES OF DEATH IN THE UNITED STATES; 2006 (DEATHS PER 100,000)</i>	83
ESTABLISHED DRUG CLASSES IN CARDIOVASCULAR DISEASE.....	84
Statins	84
Angiotensin Receptor Blocker.....	85
Angiotensin Converting Enzyme (ACE) inhibitors	85
EMERGING DRUG CLASSES.....	86
P2Y12 Inhibitors and Antagonists.....	86
Factor Xa Inhibitors	86
Cholesterol-Ester Transfer Protein (CETP) Inhibitor	87
<i>TABLE 22 CETP INHIBITORS IN ACTIVE DEVELOPMENT</i>	87
KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET	87
Plavix Metabolizer 2C19 Triggers U.S. Warning.....	87
VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR HYPERTENSION.....	88
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT	89
<i>TABLE 23 RECENTLY APPROVED DRUGS</i>	89
<i>TABLE 24 SUMMARY PIPELINE FORECAST</i>	90

INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS.....	90
INDUSTRY STRUCTURE.....	90
<i>TABLE 25 CARDIOVASCULAR MARKET SEGMENTS, SIZE,</i>	
<i>GROWTH AND SHARE, THROUGH 2010 (\$ MILLIONS).....</i>	<i>91</i>
MARKET CONCENTRATION AND PRICE SENSITIVITY.....	92
<i>TABLE 26 COMPANY BY DISEASE CLASS, 2010 REVENUE (\$</i>	
<i>MILLIONS).....</i>	<i>93</i>
MARKET TRENDS.....	94
Overall Market Flat: Higher Mix of Generics Offset by	
Higher Volume.....	94
MASSIVE PATENT EXPIRATION IS A GROWTH OPPORTUNITY	
FOR GENERICS.....	94
<i>TABLE 27 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS (\$</i>	
<i>MILLIONS).....</i>	<i>95</i>
MARKET EXPANSION VIA DISEASE PREVENTION IS THE	
FUTURE OF CARDIO CARE.....	95
ATRIAL FIBRILLATION IS A LARGE AND EMERGING DISEASE	
STATE.....	96
COMBINATION THERAPIES ARE SYNERGISTIC REVENUE	
GENERATORS.....	97
COMBINATION THERAPIES ARE ...(CONTINUED).....	98
CHAPTER FIVE: ALZHEIMER'S DISEASE THERAPEUTICS AND	
DIAGNOSTICS: GLOBAL MARKETS (PHM062A).....	99
INTRODUCTION.....	99
STUDY GOALS AND OBJECTIVES.....	99
REASONS FOR DOING THIS STUDY.....	99
SCOPE OF REPORT.....	99
INTENDED AUDIENCE.....	100
METHODOLOGY.....	100
INFORMATION SOURCES.....	100
ANALYST CREDENTIALS.....	100
RELATED BCC REPORTS.....	100
SUMMARY.....	101
<i>TABLE 28 GLOBAL MARKET FOR ALZHEIMER'S DISEASE,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>101</i>
<i>FIGURE 7 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, 2008-</i>	
<i>2014 (\$ MILLIONS).....</i>	<i>101</i>
FORECAST SUMMARY.....	102
OVERVIEW.....	103
DEFINITION AND MARKET STRUCTURE.....	103
What Is Alzheimer's Disease?.....	103
<i>TABLE 29 U.S. ALZHEIMER'S PATIENTS, 2000-2050 (MILLIONS).....</i>	<i>103</i>
<i>FIGURE 8 U.S. ALZHEIMER'S PATIENTS, 2000-2050 (MILLIONS).....</i>	<i>104</i>
Role of the Cholinergic System.....	104

Role of Beta-Amyloid Protein	105
Behavioral Manifestations of AD	106
Incidence and Prevalence	106
<i>TABLE 30 POPULATION BY SELECTED GEOGRAPHIC REGION,</i> <i>2009–2050 (MILLIONS)</i>	<i>106</i>
<i>TABLE 31 PERCENT POPULATION OVER 65, BY REGION (%)</i>	<i>107</i>
<i>TABLE 32 PEOPLE WITH ALZHEIMER’S DISEASE, BY AGE GROUP,</i> <i>2004-2050 (MILLIONS).....</i>	<i>107</i>
<i>FIGURE 9 PEOPLE WITH ALZHEIMER’S DISEASE, BY AGE GROUP,</i> <i>2004-2050 (MILLIONS).....</i>	<i>107</i>
<i>TABLE 33 PERCENTAGE OF PEOPLE WITH ALZHEIMER’S, BY AGE</i> <i>BRACKET</i>	<i>108</i>
<i>FIGURE 10 PERCENTAGE OF PEOPLE WITH ALZHEIMER’S, BY AGE</i> <i>BRACKET (%).....</i>	<i>108</i>
<i>TABLE 34 GLOBAL DISEASE PREVALENCE: ALZHEIMER’S</i> <i>DISEASE (%)</i>	<i>108</i>
STAGES OF ALZHEIMER’S DISEASE.....	109
Stages of Alzheimer’s ... (Continued)	109
Stages of Alzheimer’s ... (Continued)	109
DIAGNOSIS	111
<i>TABLE 35 DIAGNOSTIC TESTS.....</i>	<i>112</i>
How Accurate are the Screening Tests?	112
How Accurate are the ... (Continued)	113
KEY EVENTS	114
PATENT EXPIRATIONS.....	114
NEW PRODUCT LAUNCHES	114
PRICING	115
KEY MARKETS	115
<i>TABLE 36 GLOBAL MARKET FOR ALZHEIMER’S DISEASE, BY</i> <i>REGION, THROUGH 2014 (\$ MILLIONS)</i>	<i>115</i>
<i>FIGURE 11 GLOBAL MARKET FOR ALZHEIMER’S DISEASE, BY</i> <i>REGION, 2008-2014 (\$ MILLIONS).....</i>	<i>116</i>
MARKET SIZE AND KEY PLAYERS	116
 CHAPTER SIX: ANTIPSYCHOTIC DRUGS: TECHNOLOGIES AND	
GLOBAL MARKETS (PHM063A)	117
INTRODUCTION	117
STUDY GOALS AND OBJECTIVES	117
REASONS FOR DOING THIS STUDY	118
INTENDED AUDIENCE.....	118
SCOPE OF REPORT.....	119
METHODOLOGY.....	119
INFORMATION SOURCES	120
AUTHOR’S CREDENTIALS	120
RELATED BCC WORK CREDENTIALS	120

SUMMARY.....	120
<i>TABLE 37 THE WORLDWIDE MARKET FOR ANTIPSYCHOTIC DRUGS, THROUGH 2014 (\$, MILLIONS)</i>	121
<i>FIGURE 12 THE WORLDWIDE MARKET FOR ANTIPSYCHOTIC DRUGS, 2010–2014 (\$, MILLIONS)</i>	122
OVERVIEW.....	122
DEFINITION OF AN ANTIPSYCHOTIC DRUG.....	122
HISTORY OF ANTIPSYCHOTIC DRUGS.....	123
History of Antipsychotic Drugs.....	123
TYPES OF ANTIPSYCHOTICS ON THE MARKET.....	125
TYPICAL ANTIPSYCHOTICS.....	125
<i>TABLE 38 CLASSES OF TYPICAL ANTIPSYCHOTICS ON THE MARKET AND THEIR SIDE EFFECTS</i>	126
ATYPICAL ANTIPSYCHOTICS.....	127
<i>TABLE 39 CURRENTLY APPROVED ATYPICAL ANTIPSYCHOTICS ON THE MARKET</i>	128
<i>TABLE 39 (CONTINUED)</i>	129
<i>TABLE 40 FEATURES OF TYPICAL VERSUS ATYPICAL ANTIPSYCHOTICS</i>	130
<i>TABLE 41 COST OF SELECTED ATYPICAL AND TYPICAL ANTIPSYCHOTIC DRUGS (\$)</i>	130
<i>TABLE 41 (CONTINUED)</i>	131
RECEPTOR TARGETS OF ANTIPSYCHOTIC DRUGS.....	131
DOPAMINE.....	131
SEROTONIN.....	132
GLUTAMATE.....	133
TACHYKININ.....	134
GLUCOCORTICOID.....	135
SIDE EFFECTS OF ANTIPSYCHOTICS.....	135
NEUROLOGIC SIDE EFFECTS (EXTRAPYRAMIDAL SYMPTOMS).....	135
ANTICHOLINERGIC SIDE EFFECTS.....	136
CARDIOVASCULAR SIDE EFFECTS.....	137
METABOLIC SIDE EFFECTS.....	138
OTHER SIDE EFFECTS.....	138
<i>TABLE 42 COMPARISON OF SIDE EFFECT PROFILES OF ANTIPSYCHOTICS ON THE MARKET</i>	139
ANTIPSYCHOTICS IN CLINICAL DEVELOPMENT.....	139
<i>TABLE 43 ANTIPSYCHOTICS IN CLINICAL TRIALS, ORDERED BY PHASE</i>	140
<i>TABLE 43 (CONTINUED)</i>	141
<i>TABLE 44 NUMBER OF ANTIPSYCHOTICS IN CLINICAL TRIALS, BY PHASE (NUMBER / %)</i>	141

<i>FIGURE 13 ANTIPSYCHOTICS IN CLINICAL TRIALS BY PRIMARY RECEPTOR TARGET</i>	142
<i>TABLE 45 COMPANIES WITH MORE THAN ONE ANTIPSYCHOTICS IN CLINICAL TRIALS OR ON THE MARKET*</i>	143

CHAPTER SEVEN: UBIQUITIN PROTEASOME DRUGS: CANCER AND NEURODEGENERATIVE DISORDER MARKETS (PHM066A).....	144
INTRODUCTION	144
STUDY GOALS AND OBJECTIVES	144
REASONS FOR DOING THIS STUDY	144
SCOPE OF REPORT.....	144
METHODOLOGY AND INFORMATION SOURCES.....	145
INTENDED AUDIENCE.....	145
ANALYST CREDENTIALS	145
RELATED BCC REPORTS.....	146
SUMMARY.....	146
<i>TABLE 46 U.S. AND WORLDWIDE NET SALES OF VELCADE, THROUGH 2015 (\$ MILLIONS)</i>	147
<i>FIGURE 14 U.S. AND WORLDWIDE NET SALES OF VELCADE, 2007-2015 (\$ MILLIONS)</i>	148
<i>FIGURE 15 GLOBAL MARKET SHARES OF MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANIES, 2009 (%)</i>	148
<i>FIGURE 15 (CONTINUED)</i>	149
OVERVIEW OF SCIENTIFIC BACKGROUND, AND SIGNIFICANCE OF UPS RESEARCH.....	149
UBIQUITINATION PHENOMENA AND ITS MAJOR COMPONENTS	149
Enzymatic Components as Possible Drug Targets	149
<i>TABLE 47 ENZYMATIC COMPONENTS OF UBIQUITINATION/ DEUBIQUITINATION REACTION</i>	150
<i>FIGURE 16 ENZYMATIC STEPS IN UBIQUITINATION REACTION</i>	150
<i>FIGURE 17 HIERARCHICAL STRUCTURE OF UPS</i>	151
Chain Topology as a Signaling Pathway	151
PROTEASOME MACHINERY.....	152
STRUCTURE AND FUNCTION	152
PROTEASOME AS A TARGET FOR DRUG DISCOVERY	153
UBIQUITIN-LIKE MODIFIERS (UBLS)	153
<i>TABLE 48 UBLs, THEIR FUNCTION AND ASSOCIATED PATHOLOGY WITH THEIR DYSFUNCTION</i>	154
MAJOR DRUG DEVELOPMENT AND PRODUCTS IN THE UPS RESEARCH FIELD.....	155
INDUSTRY OVERVIEW	155
Proteasome as a Drug Discovery	155
Velcade: The First UPS Product	155

Chemical Structure of Velcade and Its Mechanism of Action	156
<i>FIGURE 18 CHEMICAL STRUCTURE OF BORTEZOMIB</i>	156
Pharmacodynamics, Administration, and Side Effects.....	156
Velcade Sales Market	157
Overview.....	157
<i>TABLE 49 U.S. STATISTICS FOR HEMATOLOGICAL MALIGNANCIES, 2009 (NUMBER)</i>	157
MM Symptoms and Treatment	158
General Treatment for MM Today	158
<i>TABLE 50 PROJECTED SIZE OF THE WORLDWIDE MM DRUG MARKET, 2009 AND 2018 (\$ BILLIONS)</i>	159
NHL and Mantle Cell Lymphoma.....	159
• Treatments for Mantle Cell Lymphoma and Other NHL.....	159
• CHOP Therapy.....	159
• MabThera/Rituxan.....	159
Current Major Market Participants in MM Treatment and Sales Forecast	160
Millennium Pharmaceuticals (a Subsidiary of Takeda)	160
<i>TABLE 51 U.S. AND WORLDWIDE NET SALES OF VELCADE, THROUGH 2015 (\$ MILLIONS)</i>	160
<i>FIGURE 19 U.S. AND WORLDWIDE NET SALES OF VELCADE, 2007-2015 (\$ MILLIONS)</i>	161
Celgene	161
• Revlimid	161
• Thalomid	162
<i>TABLE 52 WORLDWIDE NET SALES OF REVLIMID AND THALOMID, THROUGH 2016 (\$ MILLIONS)</i>	162
<i>FIGURE 20 WORLDWIDE NET SALES OF REVLIMID AND THALOMID, 2006-2016 (\$ MILLIONS)</i>	163
Market Shares of Millennium/Takeda, Celgene, and Other Companies' Drugs	163
<i>TABLE 53 WORLDWIDE SHARES OF THE MM TREATMENT MARKET: MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANY SHARES IN 2009 COMPARED TO THOSE PROJECTED IN 2011* (%)</i>	164
<i>FIGURE 21 WORLDWIDE SHARES OF THE MM TREATMENT MARKET: MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANY SHARES IN 2009 COMPARED TO PROJECTED SHARES IN 2011* (%)</i>	164
<i>FIGURE 21 (CONTINUED)</i>	165

Millennium Pharmaceuticals/Takeda's New Developments	165
<i>TABLE 54 EXAMPLE OF COSTS OF SIDE EFFECTS OF CHEMOTHERAPY TREATMENT PER PATIENT IN THE U.S., 2006 (\$ THOUSANDS)</i>	166
New Formulations for Velcade and Second-Generation Inhibitors	166
Improvement of Velcade	166
Second-Generation Inhibitor MLN9708	166
<i>TABLE 55 CURRENT R&D ACTIVITY IN UPS BY MILLENNIUM/TAKEDA</i>	167
Velcade in Combination with Other Treatments	167
COMPANIES WORKING ON SECOND-GENERATION PROTEASOME INHIBITORS	167
OVERVIEW	167
Current Market Participants	167
<i>TABLE 56 COMPANIES WITH CURRENT R&D IN PROTEASOME INHIBITION AS A DRUG TARGET</i>	168
Millennium Pharmaceuticals (a Subsidiary of Takeda)	168
Onyx Pharmaceuticals/Proteolix.....	168
• Carfilzomib.....	168
• ONX 0912.....	169
• ONX 0914 (PR-957).....	169
<i>TABLE 57 WORLDWIDE MARKET FOR AUTOIMMUNE DISORDERS: LUPUS, RA, AND IBD, 2008 (\$ BILLIONS)</i>	170
Cephalon.....	170
• CEP-18770	170
Nereus Pharmaceuticals.....	170
• Salinosporamide (NPI-0052)	170
Salinosporamide ... (Continued)	171
CHAPTER EIGHT: ONCOLOGY ADJUVANTS: TECHNOLOGIES AND GLOBAL MARKETS (PHM067A)	172
INTRODUCTION	172
STUDY GOALS AND OBJECTIVES	172
REASONS FOR DOING THIS STUDY	172
INTENDED AUDIENCE.....	173
SCOPE OF REPORT.....	173
METHODOLOGY.....	173
INFORMATION SOURCES	174
ANALYST CREDENTIALS	174
RELATED BCC REPORTS.....	174
SUMMARY	174

<i>TABLE 58 GLOBAL MARKET FORECAST FOR ONCOLOGY ADJUVANTS, THROUGH 2015 (\$ MILLIONS)</i>	175
<i>FIGURE 22 GLOBAL ONCOLOGY ADJUVANT SALES BY MARKET GEOGRAPHY, 2009 AND 2015 (%)</i>	176
OVERVIEW	177
HISTORY AND CURRENT STATE OF ONCOLOGY AND CONCEPTS OF ADJUVANTS IN ONCOLOGY	177
TYPES OF CANCER	178
DEFINITION OF THE INDUSTRY	179
IMPORTANCE OF THE INDUSTRY	180
PRODUCT LIFE CYCLES	180
<i>TABLE 59 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG</i>	181
DEVELOPMENT OF ONCOLOGY ADJUVANTS	181
<i>TABLE 60 HISTORICAL PIPELINE OF FDA-APPROVED ONCOLOGY ADJUVANTS</i>	182
HUMAN CLINICAL DEVELOPMENT	183
NEW DRUG ACTIVITY	183
FUTURE DEVELOPMENTS	184
2008 TO 2009 DRUG ACTIVITY	184
2008 to 2009 Drug Activity (Continued)	185
WITH AN EYE TOWARD THE FUTURE	186
TYPE OF APPLICATIONS IN THE HUMAN ONCOLOGY ADJUVANT MARKETPLACE: CHEMOTHERAPY, IMMUNOTHERAPY, AND RADIOTHERAPY	186
<i>TABLE 61 GLOBAL MARKET FORECAST FOR ONCOLOGY ADJUVANTS SALES BY PRODUCT TYPE, THROUGH 2015 (\$ MILLIONS)</i>	187
<i>FIGURE 23 ONCOLOGY ADJUVANTS SALES: BY ADJUNCTIVE PRODUCT TYPE, 2008-2015 (\$ MILLIONS)</i>	188
HUMAN CANCERS	188
<i>TABLE 62 GLOBAL MARKET FORECAST FOR ONCOLOGY ADJUVANTS BY CANCER INDICATION, THROUGH 2015 (\$ MILLIONS)</i>	189
<i>FIGURE 24 ONCOLOGY ADJUVANTS FORECAST SALES: BY TYPE OF CANCER 2008-2015 (\$ MILLIONS)</i>	189
RISK FACTORS FOR DEVELOPING CANCERS	190
<i>TABLE 63 RISK FACTORS ASSOCIATED WITH HUMAN CANCERS</i>	190
<i>TABLE 63 (CONTINUED)</i>	191
<i>TABLE 64 INCIDENCE ASSOCIATED WITH HUMAN CANCERS IN MEN</i>	192
<i>TABLE 65 INCIDENCE ASSOCIATED WITH HUMAN CANCERS IN WOMEN</i>	192

<i>TABLE 66 HUMAN CANCER TRENDS, ESTIMATED, 2008-2015 (NUMBER OF CASES)</i>	<i>193</i>
BREAST.....	193
<i>TABLE 67 GLOBAL SALES FORECAST OF BREAST CANCER ONCOLOGY ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS).....</i>	<i>194</i>
RECTUM AND COLON.....	194
<i>TABLE 68 GLOBAL SALES FORECAST OF COLORECTAL CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS).....</i>	<i>195</i>
NON-HODGKIN LYMPHOMAS.....	195
<i>TABLE 69 GLOBAL SALES FORECAST OF LYMPHOMAS ADJUVANTS BY GEORGRAPHYGEOGRAPHY, THROUGH 2015 (\$ MILLIONS).....</i>	<i>196</i>
LUNG.....	196
<i>TABLE 70 GLOBAL SALES FORECAST OF LUNG CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS).....</i>	<i>197</i>
LEUKEMIA	197
<i>TABLE 71 GLOBAL SALES FORECAST OF LEUKEMIA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS).....</i>	<i>198</i>
PROSTATE CANCER	198
<i>TABLE 72 GLOBAL SALES FORECAST OF PROSTATE CANCER ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS).....</i>	<i>198</i>
GLIOBLASTOMA	199
<i>TABLE 73 GLOBAL SALES FORECAST OF GLIOBLASTOMA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS).....</i>	<i>199</i>
MULTIPLE MYELOMA	199
<i>TABLE 74 GLOBAL SALES FORECAST OF MULTIPLE MYELOMA ADJUVANTS BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS)</i>	<i>200</i>